A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Stopped early · Phase 2

Conditions studied: Solid Tumor

In brief

A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

Key facts

Study ID
NCT04171700
Run by
pharmaand GmbH
People needed
83
Starts
2020-01-16
Expected to finish
2022-07-15
Last updated by the study team
2023-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.